This book guides medicinal chemists in how to implement early ADMET testing in their workflow in order to improve both the speed and efficiency of their efforts. Although many pharmaceutical companies have dedicated groups directly interfacing with drug discovery, the scientific principles and strategies are practiced in a variety of different ways. This book answers the need to regularize the drug discovery interface; it defines and reviews the field of ADME for medicinal chemists. In addition, the scientific principles and the tools utilized by ADME scientists in a discovery setting, as applied to medicinal chemistry and structure modification to improve drug-like properties of drug candidates, are examined.
Early ADMET explained: an integrated approach to successful drug development
This practical guide provides medicinal chemists insights into the field of early ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicology), giving them a how-to for implementing early ADMET testing in their workflows, and maximizing the success of drug candidates in preclinical and clinical studies.
The emphasis and themes illustrate the required collaboration and communication between team members from different specialties, such as chemists, biologists, formulators, toxicologists, and preclinical and clinical development specialists. The book demonstrates how this collaborative approach addresses long-standing productivity issues in the pharmaceutical industry, accelerates positive results, and helps improve the commercialization rate for therapeutic agents.
Written by a group of experts from diverse disciplines, ADMET for Medicinal Chemists covers all key areas of the drug development process, including:
* Technical considerations when selecting preclinical drug candidates
* Guidelines for how to avoid pitfalls during drug design and discovery
* Proven cutting-edge approaches to preclinical studies and drug design
* Essential computer methods for designing molecules with desired properties
* Absorption and physicochemical properties of New Chemical Entities (NCE)
* The concepts underlying pharmacokinetics
* Assays for testing cardiac safety, genetic toxicity, and hepatic toxicity
* In vivo toxicological considerations and complying with FDA requirements
